Literature DB >> 22393085

Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy.

Erin M Olson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22393085     DOI： 10.1200/JCO.2011.40.2545

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Authors:  E M Olson; M Abdel-Rasoul; J Maly; C S Wu; N U Lin; C L Shapiro
Journal:  Ann Oncol       Date:  2013-03-04       Impact factor: 32.976

2.  Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

Authors:  Senthilkumar Damodaran; Erin M Olson
Journal:  Hosp Pract (1995)       Date:  2012-10

3.  Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.

Authors:  Mellissa Hicks; Erin R Macrae; Mahmoud Abdel-Rasoul; Rachel Layman; Susan Friedman; Jenny Querry; Maryam Lustberg; Bhuvaneswari Ramaswamy; Ewa Mrozek; Charles Shapiro; Robert Wesolowski
Journal:  Oncologist       Date:  2015-03-02

Review 4.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

5.  Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

Authors:  Erin M Olson; Julie S Najita; Jessica Sohl; Amal Arnaout; Harold J Burstein; Eric P Winer; Nancy U Lin
Journal:  Breast       Date:  2013-01-23       Impact factor: 4.380

6.  Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.

Authors:  Yanjun Hou; Hiroaki Nitta; Lai Wei; Peter M Banks; Anil V Parwani; Zaibo Li
Journal:  Clin Breast Cancer       Date:  2017-11-09       Impact factor: 3.225

Review 7.  Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

Authors:  M B Smith; J Reardon; E M Olson
Journal:  Drugs Today (Barc)       Date:  2012-11       Impact factor: 2.245

Review 8.  How Structural Biologists and the Protein Data Bank Contributed to Recent FDA New Drug Approvals.

Authors:  John D Westbrook; Stephen K Burley
Journal:  Structure       Date:  2018-12-27       Impact factor: 5.006

Review 9.  Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer.

Authors:  Drew R Oostra; Erin R Macrae
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-07-23

10.  The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.

Authors:  Zhe-Ling Chen; Yan-Wei Shen; Shu-Ting Li; Chun-Li Li; Ling-Xiao Zhang; Jiao Yang; Meng Lv; Ya-Yun Lin; Xin Wang; Jin Yang
Journal:  Onco Targets Ther       Date:  2016-05-30       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.